Korhonen, P. ., Heintjes, E. M., Williams, R. ., Hoti, F. ., Christopher, S. ., Majak, M. ., … Bahmanyar, S. . (2016). Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries. Bmj. http://doi.org/10.1136/bmj.i3903
S. Bahmanyar
First name
S.
Last name
Bahmanyar
Strongman, H. ., Korhonen, P. ., Williams, R. ., Bahmanyar, S. ., Hoti, F. ., Christopher, S. ., … Heintjes, E. M. (2017). Pioglitazone and risk of mortality in patients with type 2 diabetes: results from a European multidatabase cohort study. BMJ Open Diabetes Res Care. http://doi.org/10.1136/bmjdrc-2016-000364
Margulis, A. V., Linder, M. ., Arana, A. ., Pottegard, A. ., Berglind, I. A., Bui, C. L., … Hallas, J. . (2018). Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom. PLoS One. http://doi.org/10.1371/journal.pone.0204456
Strongman, H. ., Christopher, S. ., Majak, M. ., Williams, R. ., Bahmanyar, S. ., Linder, M. ., … Hoti, F. . (2018). Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multidatabase cohort study. BMJ Open Diabetes Res Care. http://doi.org/10.1136/bmjdrc-2017-000481
Phiri, K. ., Hallas, J. ., Linder, M. ., Margulis, A. ., Suehs, B. ., Arana, A. ., … Seeger, J. . (2021). A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder. Curr Med Res Opin. http://doi.org/10.1080/03007995.2021.1891035